Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study

Conclusions The combination of daclatasvir/peginterferon-alfa/ribavirin was generally well tolerated and achieved higher SVR24 rates compared with placebo/peginterferon-alfa/ribavirin among patients infected with HCV genotype 1 or 4. Trial registration number NCT01125189.

http://gut.bmj.com/cgi/content/short/64/6/948?rss=1

Source: Gut - May 8, 2015 Category: Gastroenterology Authors: Hezode, C., Hirschfield, G. M., Ghesquiere, W., Sievert, W., Rodriguez-Torres, M., Shafran, S. D., Thuluvath, P. J., Tatum, H. A., Waked, I., Esmat, G., Lawitz, E. J., Rustgi, V. K., Pol, S., Weis, N., Pockros, P. J., Bourliere, M., Serfaty, L., Vierling, Tags: Hepatology Source Type: research